PT  - JOURNAL ARTICLE
AU  - Richmond, Rebecca C
AU  - Rejon, Carlos Sillero
AU  - Khouja, Jasmine N
AU  - Prince, Claire
AU  - Board, Alexander
AU  - Sharp, Gemma
AU  - Suderman, Matthew
AU  - Relton, Caroline L
AU  - Munafò, Marcus
AU  - Gage, Suzanne H
TI  - Investigating the DNA methylation profile of e-cigarette use
AID  - 10.1101/2021.01.28.21250699
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.28.21250699
4099  - http://medrxiv.org/content/early/2021/01/31/2021.01.28.21250699.short
4100  - http://medrxiv.org/content/early/2021/01/31/2021.01.28.21250699.full
AB  - Rationale and objectives Little evidence exists on the health effects of e-cigarette use. DNA methylation may serve as a biomarker for exposure and could be predictive of future health risk. We aimed to investigate the DNA methylation profile of e-cigarette use.Methods Among 117 smokers, 117 non-smokers and 116 non-smoking vapers, we evaluated associations between e-cigarette use and epigenome-wide methylation from saliva. We tested associations between e-cigarette use and methylation scores known to predict smoking and smoking-related disease. We assessed the ability of a methylation score for predicting e-cigarette use and for discriminating lung cancer.Measurements and Main Results 7 CpGs were identified in relation to e-cigarette use at p<1×10−5 and none at p<5.91×10−8. 13 CpGs were associated with smoking at p<1×10−5 and one at p<5.91×10−8. CpGs associated with e-cigarette use were largely distinct from those associated with smoking. There was strong enrichment of known smoking-related CpGs in the smokers but not the vapers. A methylation score for e-cigarette use showed poor prediction internally (AUC 0.55, 0.41-0.69) and externally (AUC 0.57, 0.36-0.74) compared with a smoking score (AUCs 0.80) and was less able to discriminate lung squamous cell carcinoma from adjacent normal tissue (AUC 0.64, 0.52-0.76 versus AUC 0.73, 0.61-0.85).Conclusions The DNA methylation profile for e-cigarette use is largely distinct from that of cigarette smoking, did not replicate in independent samples, and was unable to discriminate lung cancer from normal tissue. The extent to which methylation related to long-term e-cigarette use translates into chronic effects requires further investigation.What is the key question?Is there a DNA methylation signature of e-cigarette use and is it distinct from that of smoking?What is the bottom line?Smoke exposure is known to lead to widespread changes in DNA methylation which have been identified in different populations and samples, persist for many years after smoking cessation, and may act as a biomarker for smoking-related disease risk and mortality. Whether a similar methylation profile exists in relation to e-cigarette use has not been widely investigated.Why read on?We obtained saliva samples from 116 e-cigarette users and compared their DNA methylation profile with 117 smokers and 117 non-smokers. The e-cigarette users in this study had a minimal smoking history, and so we were able to distinguish the effects of e-cigarette use from those of smoke exposure. Overall, we found that the methylation profile associated with e-cigarette use is less pronounced and distinct from that associated with cigarette smoking.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Cancer Research UK Population Research Committee project grant (C57854/A22171). Further support was provided by the UK Medical Research Council (MC_UU_00011/5 and MC_UU_00011/7) which funds a Unit at the University of Bristol where R.C.R., C.S.R., J.K., C.P., G.S., M.S., C.L.R and M.M. work, and the CRUK-funded Integrative Cancer Epidemiology Programme (C18281/A19169). R.C.R is a de Pass Vice Chancellors Research Fellow at the University of Bristol. C.S.Rs time is supported by the National Institute for Health Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol NHS Foundation Trust. The UK Medical Research Council and Wellcome (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors who will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for the study was granted by the Faculty of Science Human Research Ethics Committee at the University of BristolAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesResults from the epigenome-wide association studies performed will be uploaded to the EWAS catalog (http://www.ewascatalog.org/)